Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

5(83.3%)

Phase 1

1(16.7%)

6Total

N/A(5)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01550458Phase 1Completed

Safety Study of Mibefradil When Given Four Times a Day in Healthy Volunteers

Role: collaborator

NCT02533531Not ApplicableTerminated

Proof of Concept Study for 1 Lead Patch Technology

Role: lead

NCT02524470Not ApplicableCompleted

Vital Signs Patch Early Feasibility and Usability Study v1.0

Role: lead

NCT02518100Not ApplicableCompleted

Vital Signs Patch: Automated Monitoring of Vital Signs Measurements in the In-Patient Hospital Setting

Role: lead

NCT02521922Not ApplicableCompleted

Vital Signs Patch Early Feasibility and Usability Study

Role: lead

NCT01899911Not ApplicableCompleted

Clinical Study of Peripheral Capillary Oxygen Saturation (SpO2): Vital Signs Patch (VSP)

Role: lead

NCT01410396Completed

Occult Paroxysmal Atrial Fibrillation in Patients With Non-cardioembolic Ischemic Stroke of Determined Mechanism

Role: collaborator

All 7 trials loaded